Modality
Nanobody
MOA
Anti-Aβ
Target
MDM2
Pathway
Innate Imm
RA
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
~May 2023
→ ~Aug 2024
Phase 2
Nov 2024
→ Jun 2025
Phase 2Current
NCT06287604
2,457 pts·RA
2024-11→2025-06·Recruiting
2,457 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0110mo agoPh3 Readout· RA
Trial Timeline
2025Q2
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-06-01 · 10mo ago
RA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06287604 | Phase 2/3 | RA | Recruiting | 2457 | PASI75 |
Competitors (10)